Improving access to medicines: lessons from 10 years of drug reforms in China, 2009–2020

Abstract

China initiated its healthcare reform in 2009 to provide accessible and affordable healthcare to all. We summarised China’s drug reforms between 2009 and 2020 using the WHO framework. China has initiated comprehensive drug policies to address different issues, including: (1) issuing or amending major regulations with changes in institutional settings; (2) implementing the marketing authorisation holder system and bioequivalence assessment to improve the quality of drugs; (3) leveraging accelerated market approval and insurance listing to encourage needs-driven innovation and improve the access to new drugs; (4) introducing compulsory licensing to address major public health threats when needed; (5) scaling up the National Essential Medicine Policy and introducing pharmacoeconomic evaluation in National Reimbursable Drug List to promote rational use of medicine and evidence-based selection; (6) applying differentiated pricing strategies and scaling up zero mark-up policies to form a new financing mechanism; (7) adapting bulk procurement and placing strict regulations on the supply chain management to ensure supply and reduce the cost; (8) empowering pharmacists to improve the rational use of medicine; and (9) using procurement and supply chain digital platforms to inform decision and improve efficiency. China’s drug reform has adopted a phased and systemic approach that mobilises multiple policy levers including governance, regulation and financing. Despite the progress, emerging challenges in implementation, coordination and capacity need to be addressed. Cross-cutting lessons from China’s drug reforms include aligning the drug reform with the overall health reforms, adapting a systemic approach that mobilised policy levers and stakeholders and informing policy decision by conducting pilot studies.

Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study

“…We chose the Newey model to estimate the coefficients by ordinary least squares (OLS) regression and produced Newey-West standard errors to handle autocorrelation alongside possible heteroskedasticity [31,32]. We ran all the models using the statistical software Stata/MP V. 16…”

“…The effect of the previous two rounds of NDPN was not fully satisfactory; for example, the increase in availability and utilization did not fulfil expectations, and the aforementioned lag time existed between release and implementation. Meanwhile, as a public strategic buyer, the NHSA collectively managed the selection of NRDL, national price negotiation, and procurement of innovative anticancer medicines [14][15][16]. However, prior to the establishment of NHSA, drug prices, drug payment standards, insurance listing, drug bidding, and procurement were regulated by different government departments in China [17].…”

Whether medicine supply is really meeting primary health care needs—a mixed-methods study in Shandong Province, China

“…Implementing strategies that incorporate dynamic, consistent, and prompt surveillance and early warning, augmented by coordinated reactions, has achieved notable progress, including the development of an integrated platform for acquiring medicine shortage data, a shortage-list management system, and a hierarchical and classi ed disposal system [27][28][29][30][31].…”

In Vivo Bioequivalence Study of Drug: An Analysis of Bidding in Vietnam Period 2018 - 2022

“…+ Tại Trung Quốc, từ năm 2018 các thuốc TĐSH được Cục quản lý an ninh y tế quốc gia (NHSA -National Healthcare Security Administration) ưu tiên xem xét trong mua sắm. Tính đến hết năm 2019, có 323 thuốc (323 brand names) (123 hoạt chất) đã được đánh giá TĐSH) tại Trung Quốc [9]. Từ năm 2018, Trung Quốc áp dụng chính sách "Mỗi loại thuốc không được có nhiều hơn hai nhà bán buôn và hai hóa đơnmột của nhà sản xuất và một của nhà bán buôn, tất cả đều được đăng tải lên platform mua sắm để quản lý [9].…”